1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Company
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  11:12 2022-07-01 am EDT
784.60 DKK   -0.33%
06/30NOVO NORDISK A/S : The technical configuration is positive
06/29European ADRs Move Slightly Higher in Wednesday Trading
MT
06/28NOVO NORDISK : UBS lowers its rating to Sell
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:

- products for treating diabetes and obesity (86.4%);

- hemophilia treatment products (7.3%): mainly injections of protein;

- growth hormones (5.1%): used for treatment of growth deficiencies in children;

- hormone replacement products (1.2%): used for treatment of the menopause and prevention of osteoporosis.

Net sales are distributed geographically as follows: Europe/Middle East/Africa (26.8%), the United States (44.8%), North America (3%), China (11.4%) and other (14%).

Number of employees : 47 792 people.
Sales per Business
20202021Delta
Diabetes and Obesity Care108 020.0085.1%121 597.0086.4% +12.57%
Biopharm18 926.0014.9%19 203.0013.6% +1.46%
DKK in Million
Sales per region
20202021Delta
United States57 824.0045.6%63 009.0044.8% +8.97%
EMEA34 297.0027%37 706.0026.8% +9.94%
Rest of the World17 448.0013.7%19 812.0014.1% +13.55%
China14 084.0011.1%16 019.0011.4% +13.74%
Canada3 293.002.6%4 254.003% +29.18%
DKK in Million
Managers
Name Title Age Since
Lars Fruergaard Jorgensen President & Chief Executive Officer 55 2017
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President 50 2018
Henrik Ehlers Wulff Senior Vice President-Diabetes API 51 2008
Stephen Gough Global Chief Medical Officer - 2015
Marcus Schindler Senior Vice President-Global Drug Discovery 55 2018
John McDonald Vice President-R&D, Business Development - -
Jill Priselac Vice President-R&D, Business Development - -
Maziar Mike Doustdar Senior Vice President-International Operations 51 2013
Daniel Bohsen Vice President & Head-Investor Relations - 2020
Doug Langa EVP & Head-North America Operations 55 2017
Members of the board
Name Title Age Since
Helge Lund Chairman 59 2018
Sylvie Louise Grégoire, Dr. Independent Director 59 2015
Andreas Fibig Independent Director 60 2018
Martin MacKay Independent Director 65 2018
Laurence Debroux Independent Director 52 2019
Jeppe Fonager Christiansen Vice Chairman 62 2013
Kasim Kutay Director 56 2017
Mette Bøjer Jensen Director 46 2018
Thomas Rantzau Director 49 2018
Henrik Poulsen Director 54 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 537,000,000 0 0.0% 0 0.0% 69.6%
Stock B 1 1,742,564,000 1,586,735,093 91.1% 33,526,721 1.9%
Shareholders
NameEquities%
Novo Holdings A/S (Investment Company) 110,519,000 6.34%
The Vanguard Group, Inc. 43,126,750 2.47%
Norges Bank Investment Management 39,877,804 2.29%
BlackRock Fund Advisors 28,057,815 1.61%
Capital Research & Management Co. (World Investors) 24,928,970 1.43%
BlackRock Investment Management (UK) Ltd. 21,613,860 1.24%
Fundsmith LLP 21,489,877 1.23%
Novo Nordisk A/S 14,281,381 0.82%
BlackRock Advisors (UK) Ltd. 12,827,671 0.74%
Handelsbanken Fonder AB 12,289,868 0.71%
Holdings
NameEquities%Valuation
NOVO NORDISK A/S (NOVO B) 14,281,381 0.82% 1,578,674,567 USD
NNIT A/S (NNIT) 4,375,000 17.5% 40,569,069 USD
INNATE PHARMA (IPH) 9,817,546 12.3% 29,658,119 USD
Markets and indexes
- Main Market Large
- OMX Copenhagen 25 / Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, PEA, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  NOVOB:DC
- Reuters Code :  NOVOb.CO
- Datastream Code :  
Company contact information
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsvaerd

Phone : +45 44 44 88 88
Fax : +45 44 49 05 55
web site : http://www.novonordisk.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Novo Nordisk A/S
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
NOVO NORDISK A/S6.75%248 942
JOHNSON & JOHNSON3.76%472 389
PFIZER, INC.-11.21%293 506
ELI LILLY AND COMPANY17.38%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782
MERCK & CO., INC.20.59%233 712
ASTRAZENECA PLC23.55%200 459
NOVARTIS AG0.06%181 232
BRISTOL-MYERS SQUIBB COMPANY23.24%163 597
AMGEN INC.9.15%131 173
SANOFI10.09%126 838
GSK PLC11.14%108 701
BAYER AG22.02%58 604
DAIICHI SANKYO CO., LTD.15.42%47 859
TAKEDA PHARMACEUTICAL COMPANY LIMITED19.83%42 912
CHUGAI PHARMACEUTICAL CO., LTD-6.93%42 276
JIANGSU HENGRUI MEDICINE CO., LTD.-23.21%37 069
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-19.76%31 582
ASTELLAS PHARMA INC.10.05%27 816
CATALENT, INC.-16.41%19 179